Today: 7 February 2026
Subscribe
Browse Category

TSX:RY.TO News 3 December 2025 - 25 January 2026

RBC stock has two near-term triggers: a dividend date Monday and a Bank of Canada call

RBC stock has two near-term triggers: a dividend date Monday and a Bank of Canada call

Royal Bank of Canada shares closed Friday at C$232.71 in Toronto, nearly unchanged ahead of Monday’s dividend record date and the Bank of Canada’s rate decision Wednesday. RBC raised its quarterly dividend to C$1.64 per share, payable Feb. 24. The bank will report quarterly results Feb. 26. Canada’s main stock index ended at a record high Friday, lifted by gains in gold and oil.
25 January 2026
··
RBC stock price holds near C$235 after TSX record close — what to watch before Monday

RBC stock price holds near C$235 after TSX record close — what to watch before Monday

Royal Bank of Canada shares closed nearly flat Friday at C$235.42 in Toronto, up 0.03%. The Canadian dollar fell 0.2% to 1.3915 per U.S. dollar, its lowest since December 5. RBC issued €1 billion in floating-rate notes and €750 million in fixed-to-floating notes. Investors await December inflation data and the Bank of Canada’s upcoming policy announcement.
17 January 2026
···
RBC stock: What to know before markets reopen after Canada’s jobs report

RBC stock: What to know before markets reopen after Canada’s jobs report

Canada’s unemployment rate rose to 6.8% in December, despite 8,200 new jobs, Statistics Canada said Friday. Royal Bank of Canada shares closed up 0.2% in Toronto at C$235.52, while the U.S. listing slipped 0.2% to $169.19. The Canadian dollar fell 0.3% for its biggest weekly drop in nearly a year. Investors are watching for U.S. Supreme Court rulings Jan. 14 and the Bank of Canada meeting Jan. 28.
11 January 2026
···
Royal Bank of Canada (RY, RY.TO) Stock: Q4 2025 Earnings Beat, Dividend Hike and 2026 Outlook

Royal Bank of Canada (RY, RY.TO) Stock: Q4 2025 Earnings Beat, Dividend Hike and 2026 Outlook

Published December 3, 2025 – Informational article, not investment advice. Royal Bank of Canada stock is back in the spotlight after the country’s largest lender delivered record fiscal 2025 results, raised its dividend and lifted its profitability target for 2026. With the share price hovering near all‑time highs and analyst targets pointing to only modest upside, investors are asking the obvious question: is RBC stock still a buy after this big run? Below is a detailed look at today’s news, the latest numbers and what analysts now expect for Royal Bank of Canada (TSX: RY, NYSE: RY). Where Royal Bank
3 December 2025
····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop